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PCR	product	 Variable	 -	 -	
Control	Insert	DNA	 -	 2	 -	
T4	DNA	Ligase	2	 1	 1	 1	
dH2O	 Variable	 1	 3	
































































































































































































































































































































































































































































anti-rabbit-HRP	 Cell	signaling	 7074	 Western	blot	(1:5000)	

















































































































































































































































































































chest	wall	 27.5	 1.83	 2.4	
B	 026936AUB13	
16M	metastatic	OS	to	
lung	 317.5	 1.93	 2.13	
C	 018344AUB14	 26M	OS	R	ilium		 126.9	 2.08	 2.57	
D	 UB003650/11	 15M	OS	L	fibula	 233.4	 2	 2.24	
E	 2234UB041B	
F57	post	irradiation	OS	
L	humerus	 50.3	 2.06	 4	
F	 15327UB052	 Unknown	 62.9	 1.74	 1.47	
G	 019083BUB13	 16	M	OS	R	tibia	 461.7	 1.78	 1.9	
H	 495801FUB06	 Unknown	 11611.6	 1.94	 2.11	
I	 027790UB13	
M85	Pagets	OS	
biopsy**	 117.2	 2	 1.61	
J	 028977BUB13	
M85	Pagets	OD	
resection	 404.5	 1.87	 2	
K	 21687AUB07	
F70	post-irradiation	OS	
scapula	 407.8	 1.9	 1.95	
L	 0242302UB14	 F68	R	tibia	OS	 203.1	 1.92	 2.04	




chemotherapy	 325.3	 1.83	 1.91	
O	 020619AUB14	 M9	R	humerus	 74	 1.89	 1.78	
P	 004550UB15	
26M	recurrent	OS	post	













viable	 30.9	 1.73	 1.32	
T	 UB005790/111A	
M59	metastatic	OS	to	









































































































































1	 M	 15/01/42	 6929/91	 Y	 Pre-treatment	 Hip	
2	
	 M	 16/03/34	
4331/92	 Y	 Pre-treatment	 Proximal	femur	
7401/92	 Y	 Post-treatment	 Proximal	femur	
3	 M	 22/05/47	 22560/92	 Y	 Post-treatment	 Proximal	tibia	






15886/95	 Y	 Pre-treatment	 Humerus	
19846/95	 N	 Post-treatment	 Humerus	







12089/96	 Y	 Post-treatment	 Parosteal	OS	present	in	femur	





8	 Unknown	 Unknown	 27209/96	
N	
Pre-treatment	 Low	grade	in	scapula	
9	 Unknown	 Unknown	 27212/96	
N	
Pre-treatment	 Tibia	
10	 M	 12/05/81	 5228/98	 Y	 Pre-treatment	 Unknown	



















14	 F	 18/03/77	 8348/02	 Y	 Pre-treatment	 Femur	
15	 F	 26/01/91	 20660/02	 Y	 Pre-treatment	 Femur	


























18	 F	 19/03/88	 9422/05	 Y	 Pre-treatment	 Femur	
19	 M	 06/02/90	
28026/05	 Y	 Pre-treatment	 Femur	
5199/06	 Y	 Pre-treatment	 Femur	
20	 M	 26/04/90	


















23	 M	 19/08/44	 7213/08	 Y	 Pre-treatment	 Tibia	
24	 F	 14/04/35	
1320/09	 Y	 Pre-treatment	 Scapula	
5399/09	 N	 Post-treatment	 Scapula	
25	 F	 22/05/42	
8216/09	 Y	 Pre-treatment	 Maxilla	

























16790/09	 N	 Pre-treatment	 Chondroblastic	OS	present	in	ribs	











28	 M	 02/12/22	 27824/09	 Y	 Post-treatment	 Humerus	






23235/11	 Y	 Pre-treatment	 Femur	
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Mice	were	also	scanned	at	the	experiment	end-point	using	a	microCT	scanner.	Using	
reconstruction	software,	bone	volume,	cortical	thickness,	medullary	cavity	diameter	and	
cortical	diameter	were	calculated.	3D	bone	reconstruction	models	were	also	produced.	
Mice	were	scanned	and	images	were	analysed	following	guidelines	set	out	by	Campbell	and	
Sophocleous	(2014).		
	
The	microCT	scans	show	that	there	is	no	significant	difference	between	143B	and	143B-
CSPG4	group	for	any	of	the	bone	measurements	(Figure	6.5).	Interestingly,	the	two	sham	
mice	demonstrated	bone	characteristics	at	the	experiment	end-point	that	were	very	similar	
to	the	experimental	groups.	3D	images	demonstrate	tibia	from	(Figure	6.5).	The	tumour	leg	
from	the	143B	group	(Figure	6.5e,	lower	left	panel)	represents	the	most	extreme	sample.	
This	was	not	representative	of	other	legs,	where	little	osteolytic	damage	was	seen,	as	
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demonstrated	by	the	tumour	sample	from	group	143B-CSPG4	(Figure	6.53,	lower	right	
panel).	Therefore,	CSPG4	overexpression	does	not	appear	to	influence	tumour	growth	in	
vivo,	metastatic	spread	or	alter	bone	characteristics.		
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Sham 
Tumour 
143B-CSPG4 143B 
(A) 
(C) 
(B) 
(D) 
(E) 
	Figure	6.5	–	microCT	analysis	of	bone	characteristics	between	143B	and	143B-CSPG4	orthotopic	
tumours.	Five	mice	per	group	were	injected	with	tumour	cells		for	35	days.	Mice	were	then	scanned	at	
the	experiment	end-point.	One	mouse	per	group	had	a	sham	injection	of	PBS.		(A)	Value	for	bone	
volume		(B)		Volume	for	cortical	thickness	(C)	Volume	for	medullary	cavity	diameter		(D)	Volume	for	
cortical	diameter	(E)	3D	tibia	reconstruction	images	demonstrating	the	extent	of	bone	destruction	for	
sham-injections	and	injections	of	tumour	cells,		both	143B	and	143B-CSPG4.	Experimental	group	values	
are	the	average	of	five	mice	and	the	sham.	
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6.5	Discussion	
	
The	aim	of	this	chapter	was	to	optimise	an	in	vivo	model	using	athymic	nude	mice	and	use	it	
to	assess	CSPG4	mediation	of	tumour	growth	and	metastatic	spread.	Firstly,	the	143B	cell	
line	would	be	grown	through	subcutaneous	injections	with	mice	investigated	for	tumour	
growth.	Secondly,	143B	cells	would	be	injected	intratibially	and	investigated	for	tumour	
growth	and	metastatic	growth.		
	
143B	cells	successfully	grew	in	vivo	when	injected	subcutaneously	(Figure	6.1).	This	is	
consistent	with	other	reports	that	have	demonstrated	this	finding	(Sun	et	al.	2015).	
Orthotopic	models	provide	a	more	relevant	way	to	model	osteosarcoma	growth.	A	study	by	
Luu	et	al.	(2005)	provided	evidence	that	143B	cells	could	be	injected	intratibially	where	they	
grew	and	gave	rise	to	spontaneous	pulmonary	metastasis.	1x106	cells	were	injected	in	to	
male	athymic	nude	mice	ages	four	to	six	weeks	(Luu	et	al.	2005).	In	this	study,	two	xell	
numbers,	1x106	and	2x106,	were	injected	into	separate	mice.	143B	cell	numbers	were	able	
to	grow	following	intratibial	injection	(Figure	6.2).	1x106	mice	displayed	more	consistent	
growth	between	the	two	mice,	whereas	the	2x106	mice	were	less	consistent	(Figure	6.2a).	
Metastatic	spread	was	seen	with	all	four	mice	(Figure	6.2d).	Therefore,	1x106	cells	was	the	
injection	number	taken	forward.	
	
Using	intratibial	injections	of	1x106	cells,	the	143B,	143B-CSPG4,	H10-KO	and	H10-KO-
CSPG4.	H10-KO	and	H10-KO-CSPG4	were	chosen	for	in	vivo	study	as	they	demonstrated	
similar	in	vitro	growth	rates	to	the	parental	143B	cell	line.	Expression	of	CSPG4	did	not	
appear	to	influence	tumour	growth,	metastatic	spread	or	mouse	survival.	Growth	and	
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survival	differed	both	within	groups	and	between	groups	with	no	obvious	pattern.	
Metastatic	spread	to	the	lungs	was	not	observed	in	any	of	the	mice	studied.		
	
The	lack	of	consistency	within	experimental	groups	and	lack	of	metastatic	spread	is	not	
consistent	with	published	reports.	Luu	et	al.	(2005)	found	that	the	143B	cell	line	
demonstrated	observable	tumours	by	5	days	and	tumours	continued	to	grow	until	mice	
were	culled.	In	addition,	143B	cells	readily	metastasised	to	the	lungs.	These	findings	could	
not	have	been	related	to	CSPG4	expression	as	growth	was	inconsistent	for	all	experimental	
groups.		
	
In	order	to	explain	this	result,	the	experiment	was	repeated	with	the	143B	and	143B-CSPG4	
cell	lines.	In	addition,	mice	were	scanned	at	the	experimental	end-point	to	observe	bone	
destruction.	As	a	control,	one	mouse	per	group	received	a	sham	injection	of	PBS	in	order	to	
discount	bone	remodelling	or	destruction	as	a	result	of	surgery.	Both	cell	lines	exhibited	
tumour	growth	in	this	experiment	(Figure	6.4).	However,	CSPG4	did	not	appear	to	influence	
growth,	as	the	143B	cell	line	exhibited	a	faster	growth	rate.	Metastasis	was	not	observed	in	
any	of	the	mice	injected.	
	
microCT	allows	investigation	of	bone	characteristics.	Mice	were	scanned	at	the	
experimental	end-point.	Both	the	143B,	143B-CSPG4	and	the	sham	mice	did	not	statistically	
differ	in	any	of	the	metrics	investigated,	such	as	bone	volume,	cortical	thickness,	medullary	
cavity	diameter	or	cortical	diameter	(Figure	6.5).	Therefore,	tumour	growth	over	35	days	did	
not	appear	to	cause	more	bone	destruction	than	a	sham	injection.	This	varied	within	the	
mice	as	one	mouse	(displayed	in	Figure	6.5e	lower	left	panel).		
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These	results	raise	questions	about	the	reproducibility	and	therefore,	the	validity	of	using	
the	tibia	for	injection	of	tumour	cells.	The	lack	of	consistency	of	results	(displayed	in	Figure	
6.3)	undermines	the	model’s	ability	to	produce	reliable	data.	A	number	of	technical	issues	
could	contribute	to	this.	Firstly,	injection	of	the	tumour	cells	is	not	precise	as	the	volume	
injected	depends	on	intramedullary	space.	Cells	are	injected	into	the	hole	made	in	the	
proximal	tibia	until	cells	leak	from	the	distal	hole.	Therefore,	the	amount	injected	depends	
on	the	individual	mouse	and	on	speed	of	injection.	1x106	cells	in	100uL	means	that	even	
slight	variation	in	volume	can	mean	a	large	change	in	tumour	cells.	The	leakiness	of	an	
intratibial	injection	is	increased	by	the	lack	of	space	offered	by	the	tibia.	Volume	injected	
into	the	intramedullary	space	increases	pressure	which	increases	leaks	(Sasaki	et	al.	2015).	A	
high	intramedullary	space	can	also	cause	venous	emboli,	causing	tumour	cells	to	enter	the	
bloodstream	directly.	This	could	be	a	possible	cause	for	the	high	tumour	burden	observed	in	
mouse	2x106	A	(Figure	6.2d).	A	second	issue	arises	from	tumour	cells	leaking	into	the	
surrounding	soft	tissue,	whilst	effort	is	made	to	remove	these	with	PBS,	some	could	remain.	
Tumour	cells	implanting	and	growing	in	soft	tissue	could	appear	earlier,	distorting	growth	
occurring	within	the	bone.	
	
The	limitations	of	space	and	leakiness	has	been	addressed	by	Sasaki	et	al.	(2015).	They	
propose	using	intrafemoral	injections.	The	femur	is	larger	and	is	less	bowed,	offering	more	
intramedullary	space.	The	use	of	one	injection	site	which	is	then	covered	by	bone	wax	acts	
to	reduce	leakiness	(Sasaki	et	al.	2015).	Using	this	model,	metastasis	was	observed	to	the	
liver	and	to	the	lungs	(Sasaki	et	al.	2015).		
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Another	issue	could	have	been	length	of	surgery.	Five	mice	operated	on	by	one	technician	
means	cells	can	sit	on	ice	for	considerable	time.	If	left	on	ice	for	too	long	or	if	using	the	
same	needle	on	more	than	~3	mice,	cell	sedimentation	can	occur	which	could	lead	to	
unequal	distribution	within	the	liquid	(Sasaki	et	al.	2015).	This	could	then	lead	to	different	
cell	numbers	being	injected.		
	
Another	technical	issue	with	the	injections	directly	into	the	bone	cavity,	be	that	of	the	tibia	
or	the	femur,	is	accurate	measurement.	Palpable	tumour	growth	may	differ	between	mice	
and	depends	on	observer	measurement.	Cells	expressing	a	fluorescent	marker	detectable	
by	imaging	could	represent	a	quantifiable	way	to	measure	tumour	growth	in	vivo.	
	
Therefore,	future	experiments	should	focus	on	using	the	intrafemoral	injection	with	cell	
lines	transfected	with	a	fluorescence	marker.	Future	studies,	should	investigate	the	tumour	
potential	of	143B	cell	lines	that	have	been	immunosorted	for	CSPG4	expression.	This	would	
avoid	single	cell	clones	being	used	with	the	inherent	clonal	variation.	This	would	allow	a	
quick	and	straight	forward	mechanism	of	clarifying	CSPG4’s	contribution	to	tumour	growth	
and	metastasis	in	vivo	unhindered	by	clonal	variation.	
	
190	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Chapter	7	
	
Discussion	
	
191	
7.1	Discussion	
	
Osteosarcoma	is	the	most	common	malignancy	of	bone,	which	is	common	in	
children	and	adolescence.	Since	the	advent	of	neoadjuvant	chemotherapy	four	
decades	ago,	no	new	treatments	have	emerged.	Osteosarcoma	tumours	are	
aggressive	and	prone	to	developing	resistance	to	chemotherapy	and	undergo	distal	
metastasis.	CSPG4	is	a	transmembrane	proteoglycan	molecule	involved	in	progenitor	
cell	proliferation	and	migration	(Stallcup	and	Huang	2008).	It	has	been	identified	on	
a	number	of	tumour	types	and	associated	with	proliferation,	migration,	
chemoresistance,	invasion	and	metastasis.	Preliminary	experiments	revealed	CSPG4	
expression	on	osteosarcoma	cell	lines	and	patient	samples.	The	main	aim	of	this	
study	was	to	investigate	the	role	CSPG4	plays	in	osteosarcoma	tumorigenesis	and	
whether	it	represented	a	novel	therapeutic	target.	
	
In	chapter	3,	it	was	demonstrated	that	CSPG4	expression	was	found	on	patient	
samples	and	model	cell	lines.	Both	mRNA	and	protein	expression	was	found.	mRNA	
expression	was	overexpressed	compared	to	healthy	mature	osteoblast	cells.	As	
discussed,	the	relevance	of	this	finding	depends	on	whether	mature	osteoblasts	
represent	the	cell	of	origin.	Further	experiments	should	investigate	whether	
transcript	level	can	predict	clinicopathological	features,	based	on	a	study	by	Benassi	
et	al.	(2009)	who	investigated	CSPG4	in	soft	tissue	sarcomas.	This	may	identify	
CSPG4	as	a	biomarker	for	osteosarcoma.		
	
Furthermore,	86%	of	samples	from	a	TMA	were	positive	for	CSPG4	protein	
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expression.	This	is	an	important	finding	for	a	disease	that	exhibits	vast	tumour	
heterogeneity	(Poos	et	al.	2015).	It	was	also	demonstrated	that	CSPG4	featured	on	a	
number	of	osteosarcoma	sub-types.	More	samples	would	be	needed	to	definitively	
answer	if	CSPG4	is	expressed	widely	on	all	osteosarcoma	subtypes.	Due	to	its	wide	
expression	pattern,	CSPG4	represents	a	novel	therapeutic	target.		
	
In	chapter	4,	CSPG4	expression	was	modulated	in	osteosarcoma	cell	lines	using	
CRISPR/Cas9	and	siRNA	technology.	CRISPR/Cas9	treatment	of	the	143B	cell	line	
deleted	CSPG4	protein	expression	through	selective	sequence	deletion	within	the	
CSPG4	gene.	Protein	expression	was	unidentifiable	through	western	blotting	and	
flow	cytometry	analysis.	CSPG4	cDNA	was	introduced	into	knock-out	cell	lines	and	
CSPG4	was	successfully	re-expressed.	This	was	found	predominantly	around	the	cell	
membrane	in	2	out	of	3	cell	lines.	Localisation	of	exogenously	expressed	CSPG4	
should	be	compared	to	localisation	in	the	parental	cell,	especially	in	terms	of	co-
localisation	with	known	protein	interactors.	Furthermore,	siRNA	treatment	was	
utilised	to	downregulate	CSPG4	expression.	CSPG4	protein	expressed	was	reduced	in	
U2OS,	MG63	and143B	osteosarcoma	cell	lines,	as	well	as	the	U87MG	glioblastoma	
cell	line.		
	
In	chapter	5,	no	difference	was	found	between	CSPG4-positive	and	CSPG4-negative	
or	CSPG4-reduced	cell	lines	for	cell	proliferation,	adhesion,	spreading,	migration,	
chemoresistance	or	anchorage-independent	growth.	Future	experiments	should	
investigate	the	growth	factor	dependent	influence	on	proliferation	and	migration	for	
CSPG4-positive	and	CSPG4-negative	cells,	given	CSPG4’s	role	as	a	co-receptor	for	FGF	
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and	PDGF	signalling	pathways.	Indeed,	cells	may	have	been	able	to	proliferate	at	the	
same	rate	using	growth	factors	in	the	growth	medium	unrelated	to	CSPG4	
expression.	siRNA	treatment	of	the	U87MG	cell	line	also	failed	to	alter	viability.	
Targeting	of	CPSG4	in	an	U87MG	allograft	in	vivo	led	to	attenuated	tumour	cell	
proliferation	(Poli	et	al.	2013).	This	demonstrates	that	in	the	right	environment	
CSPG4	does	contribute	to	U87MG	proliferation.	This	may	also	depend	on	the	
influence	of	relevant	growth	factors,	such	as	PDGF.	
	
It	may	also	be	the	case	that	the	role	CSPG4	plays	in	osteosarcoma	is	missed	due	to	
CRISPR/Cas9	editing	producing	unrepresentative	cell	lines.	The	single	cell	cloning	
aspect	of	CRIPR/Cas9	deletion	mean	clonal	variation	can	limit	the	usefulness	of	cells	
produced	(Veres	et	al.	2015).	It	could	also	produce	cell	lines	that	did	not	depend	on	
CSPG4	to	survive,	whilst	those	that	did,	are	unable	to	grow	and	die.	Given	the	extent	
to	which	osteosarcoma	cells	undergo	mutations	in	culture,	variations	within	a	
heterogeneous	cell	line	could	potentially	be	large.	It	could	also	be	possible	that	the	
negative	results	seen	are	a	specific	result	relating	to	the	143B	cell	line.	Future	
experiments	should	focus	on	using	siRNA	treated	cell	lines	to	investigate	functions	
not	investigated	in	this	study	such	as	adhesion,	spreading,	migration	and	
chemoresistance.		
	
As	previously	mentioned,	the	localisation	of	CSPG4	in	exogenously	expressing	cell	
lines	may	not	be	in	the	correct	proximity	to	other	proteins	it	interacts	with.	For	
example,	many	of	the	functions	that	CSPG4	mediates,	rely	on	other	proteins	such	as	
integrins	and	growth	factor	receptors.	The	143B	cell	line	should	be	investigated	for	
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whether	it	contains	complementary	integrins	or	growth	factor	receptors.		
	
In	chapter	5,	it	was	investigated	whether	proof-of-principle	evidence	could	be	
provided	for	therapeutic	targeting	of	CSPG4	on	osteosarcoma	cells,	using	an	sc-Fv	
antibody	fragment	linked	to	Pseudomonas	exotoxin	A	(ETA).	Reduced	viability	of	the	
CSPG4-negative	TC71	cell	line	was	observed	following	treatment	of	the	drug.	This	
suggests	that	an	indirect	mechanism	is	causing	toxicity,	not	specific	binding	of	the	
antibody	fragment	to	CSPG4	and	subsequent	internalisation	of	ETA.	
	
Given	the	expression	pattern	observed	of	CSPG4	on	osteosarcoma	patient	samples,	
it	remains	a	viable	therapeutic	target.	Indeed,	CSPG4	has	been	utilised	for	targeting	
of	osteosarcoma.	Treatment	of	MG63	and	U2OS	cells	with	the	anti-CSPG4	225.28	
antibody	inhibits	cell	growth	by	~60%,	significantly	higher	than	treatment	with	a	
control	mAb	(Campoli	et	al.	2010,	Wang	et	al.	2013).	Treatment	of	MG63	cells	was	
associated	with	the	downregulation	of	several	proteins,	such	as	pFAK,	pAkt,	pPDK1	
and	PKCr	(Wang	et	al.	2013)	Furthermore,	treatment	of	U2OS	with	225.28	was	found	
to	reduce	migration	by	55%	(Wang	et	al.	2013).	Targeting	of	143B	cells	with	a	CSPG4-
directed	CAR	and	T-cells	resulted	in	40%	cell	lysis	(Tschernia	et	al.	2014).	This	
demonstrates	that	CSPG4	expression	can	be	exploited	for	therapeutic	gain	in	
osteosarcoma.		
	
Recent	work	by	Salanti	et	al.	(2015)	has	demonstrated	that	CSPG4	can	be	targeted	
using	rVAR2	recombinant	protein.	rVAR2	is	a	recombinant	version	of	the	VAR2CSA	
protein	which	binds	to	placental	chondroitin	sulphate	chains	(CS	A).	CS	A	is	present	
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on	a	number	of	tumour	types,	whilst	not	being	present	on	healthy	tissues.	The	study	
demonstrated	that	CSPG4,	as	well	as	other	proteins,	are	modified	with	CS	A	and	
CSPG4	can	be	pulled-down	using	the	rVAR2	protein.	Therefore,	a	conjugated	version	
of	rVAR2,	bound	to	hemiasterlin	was	used	to	kill	U2OS,	MG63	and	HOS-MNNG	cell	
lines	(Salanti	et	al.	2015).	Further	work	has	demonstrated	that	rVAR2	treatment	of	
U2OS	and	MG63	cells	reduces	their	attachment	to	fibronectin,	collagen-I	and	
collagen-V	(Clausen	et	al.	2016).	Treatment	of	MG63	cells	with	rVAR2	also	reduces	
migration,	invasion	and	anchorage-independent	growth	(Clausen	et	al.	2016).	
Further	work,	not	on	osteosarcoma,	demonstrated	that	metastatic	lesions,	which	
display	CS	A	(or	oncofetal	CS)	can	be	targeted	with	rVAR2	(Clausen	et	al.	2016).	
Therefore,	targeting	post-translational	modifications	(such	as	CS	chains)	shared	by	a	
number	of	proteins	on	tumour	cells	could	represent	a	more	efficacious	way	to	kill	
tumour	cells.	Future	experiments	should	focus	on	investigating	whether	the	rVAR2	
protein	can	be	used	to	target	osteosarcoma	cell	lines,	in	vitro	and	in	vivo.	
	
In	chapter	6,	an	in	vivo	model	was	optimised	for	143B	cell	implantation	into	athymic	
nude	mice.	143B	cells	were	shown	to	grow	when	injected	subcutaneously	and	into	
the	tibia.	Evidence	of	metastasis	was	also	observed.	However,	results	from	intratibial	
injections	of	143B,	143B-CSPG4,	H10-KO	and	H10-KO-CSPG4	were	inconclusive.	
Large	variation	existed	between	and	within	groups.	This	could	have	been	due	to	
limitations	of	the	intratibial	injection	model,	discussed	earlier.	A	repeat	experiment	
with	intratibial	injections	of	143B	and	143B-CSPG4	produced	more	consistent	growth	
within	groups.	However,	the	143B-CSPG4	tumours	grew	slower	and	were	smaller	at	
the	experimental	end-point	suggesting	that	CSPG4	does	not	influence	osteosarcoma	
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tumour	growth	in	vivo.	Metastatic	spread	was	not	seen	in	any	mouse	for	either	
group.		Bone	characteristics	measured	through	microCT	scanning	did	not	reveal	any	
difference	between	the	two	groups.	Future	work	should	focus	on	using	intrafemoral	
injections	which	have	fewer	drawbacks	(Sasaki	et	al.	2015).	Given	the	clonal	
variation	and/or	mutation	that	may	occur	to	single	cell	clones	in	culture,	the	focus	
for	future	experiments	should	focus	on	143B	cells	immunosorted	for	CSPG4	in	the	
first	instance.	This	should	ensure	that	the	only	difference	between	groups	is	level	of	
CSPG4	protein	expression.	Furthermore,	if	metastatic	spread	could	not	be	replicated	
in	future	studies,	the	tail	injection	method	should	be	utilised	to	observe	whether	
CSPG4	expression	enhances	colonisation.	
	
In	conclusion,	this	study	has	failed	to	identify	any	functional	roles	for	CSPG4	in	
osteosarcoma	both	in	vitro	and	in	vivo.	However,	CSPG4	has	a	wide	expression	
across	osteosarcoma	samples	and	therefore	remains	a	viable	therapeutic	target	in	
osteosarcoma.
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